1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

D.B. Daniel; C.M. Rudin; L. Hart; D.R. Spigel; M.J. Edelman; J. Goldschmidt; R. Bordoni; B. Glisson; T.F. Burns; A. Dowlati; G. Dy; T.J. Beck; R. Jotte; S.V. Liu; A. Kapoun; L. Faoro; A.C. Chiang

doi:10.1093/ANNONC/MDX386.004

1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

D.B. Daniel
, C.M. Rudin
, L. Hart
, D.R. Spigel
, M.J. Edelman
, J. Goldschmidt
, R. Bordoni
, B. Glisson
, T.F. Burns
, A. Dowlati
, G. Dy
, T.J. Beck
, R. Jotte
, S.V. Liu
, A. Kapoun
, L. Faoro
, A.C. Chiang

Oncology, Tennessee Oncology, Chattanooga, TN, USA
Memorial Sloan-Kettering Cancer Center
Wake Forest University
Sarah Cannon Research Institute
Fox Chase Cancer Center
Clinical Research, Blue Ridge Cancer Care, Blacksburg, USA
Northside Hospital
University of Texas MD Anderson Cancer Center
University of Pittsburgh
Department of Medicine-Hematology and Oncology, University Hospital Cleveland Medical Center, Cleveland, OH, USA
Roswell Park Cancer Institute
Medical Oncology, Highlands Oncology Group, Fayetteville, USA
Oncology/Hematology, Rocky Mountain Cancer Center, Denver, CO, USA
Georgetown University
Translational Medicine, OncoMed Pharmaceuticals, Redwood City, USA
Clinical Development, OncoMed Pharmaceuticals, Redwood City, CA, USA
Yale University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	28
DOIs	https://doi.org/10.1093/ANNONC/MDX386.004
State	Published - Sep 1 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1093/ANNONC/MDX386.004License: Unspecified

Cite this

Daniel, D. B., Rudin, C. M., Hart, L., Spigel, D. R., Edelman, M. J., Goldschmidt, J., Bordoni, R., Glisson, B., Burns, T. F., Dowlati, A., Dy, G., Beck, T. J., Jotte, R., Liu, S. V., Kapoun, A., Faoro, L., & Chiang, A. C. (2017). 1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals of Oncology, 28. https://doi.org/10.1093/ANNONC/MDX386.004

1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). / Daniel, D.B.; Rudin, C.M.; Hart, L. et al.
In: Annals of Oncology, Vol. 28, 01.09.2017.

Research output: Contribution to journal › Article › peer-review

Daniel, DB, Rudin, CM, Hart, L, Spigel, DR, Edelman, MJ, Goldschmidt, J, Bordoni, R, Glisson, B, Burns, TF, Dowlati, A, Dy, G, Beck, TJ, Jotte, R, Liu, SV, Kapoun, A, Faoro, L & Chiang, AC 2017, '1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)', Annals of Oncology, vol. 28. https://doi.org/10.1093/ANNONC/MDX386.004

Daniel DB, Rudin CM, Hart L, Spigel DR, Edelman MJ, Goldschmidt J et al. 1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals of Oncology. 2017 Sep 1;28. doi: 10.1093/ANNONC/MDX386.004

@article{b6f32875952b49aca5b3853b66cbb26c,

title = "1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)",

author = "D.B. Daniel and C.M. Rudin and L. Hart and D.R. Spigel and M.J. Edelman and J. Goldschmidt and R. Bordoni and B. Glisson and T.F. Burns and A. Dowlati and G. Dy and T.J. Beck and R. Jotte and S.V. Liu and A. Kapoun and L. Faoro and A.C. Chiang",

note = "Background: Notch signaling is implicated in cancer stem cell biology and is an appealing target in the treatment of SCLC. TRXT, a fully human anti-Notch2/3 antibody, has shown preclinical efficacy in SCLC. A randomized phase 1b/2 study was conducted. Methods: This was a randomized, placebo-controlled, multi-center study.",

year = "2017",

month = sep,

day = "1",

doi = "10.1093/ANNONC/MDX386.004",

language = "American English",

volume = "28",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Elsevier",

}

TY - JOUR

T1 - 1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

AU - Daniel, D.B.

AU - Rudin, C.M.

AU - Hart, L.

AU - Spigel, D.R.

AU - Edelman, M.J.

AU - Goldschmidt, J.

AU - Bordoni, R.

AU - Glisson, B.

AU - Burns, T.F.

AU - Dowlati, A.

AU - Dy, G.

AU - Beck, T.J.

AU - Jotte, R.

AU - Liu, S.V.

AU - Kapoun, A.

AU - Faoro, L.

AU - Chiang, A.C.

N1 - Background: Notch signaling is implicated in cancer stem cell biology and is an appealing target in the treatment of SCLC. TRXT, a fully human anti-Notch2/3 antibody, has shown preclinical efficacy in SCLC. A randomized phase 1b/2 study was conducted. Methods: This was a randomized, placebo-controlled, multi-center study.

PY - 2017/9/1

Y1 - 2017/9/1

UR - https://www.annalsofoncology.org/article/S0923-7534(20)38715-9/fulltext

U2 - 10.1093/ANNONC/MDX386.004

DO - 10.1093/ANNONC/MDX386.004

M3 - Article

SN - 1569-8041

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

ER -

1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

Disciplines

Access to Document

Other files and links

Cite this